A novel inborn error of the coenzyme Q10 biosynthesis pathway: cerebellar ataxia and static encephalomyopathy due to COQ5 C‐methyltransferase deficiency
Primary coenzyme Q10 (CoQ10; MIM# 607426) deficiencies are an emerging group of inherited mitochondrial disorders with heterogonous clinical phenotypes. Over a dozen genes are involved in the biosynthesis of CoQ10, and mutations in several of these are associated with human disease. However, mutatio...
Saved in:
Published in: | Human mutation Vol. 39; no. 1; pp. 69 - 79 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
United States
Hindawi Limited
01-01-2018
|
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Primary coenzyme Q10 (CoQ10; MIM# 607426) deficiencies are an emerging group of inherited mitochondrial disorders with heterogonous clinical phenotypes. Over a dozen genes are involved in the biosynthesis of CoQ10, and mutations in several of these are associated with human disease. However, mutations in COQ5 (MIM# 616359), catalyzing the only C‐methylation in the CoQ10 synthetic pathway, have not been implicated in human disease. Here, we report three female siblings of Iraqi‐Jewish descent, who had varying degrees of cerebellar ataxia, encephalopathy, generalized tonic‐clonic seizures, and cognitive disability. Whole‐exome and subsequent whole‐genome sequencing identified biallelic duplications in the COQ5 gene, leading to reduced levels of CoQ10 in peripheral white blood cells of all affected individuals and reduced CoQ10 levels in the only muscle tissue available from one affected proband. CoQ10 supplementation led to clinical improvement and increased the concentrations of CoQ10 in blood. This is the first report of primary CoQ10 deficiency caused by loss of function of COQ5, with delineation of the clinical, laboratory, histological, and molecular features, and insights regarding targeted treatment with CoQ10 supplementation.
Malicdan, Vilboux, Ben‐Zeev, et al., describe a new primary coenzyme Q10 (CoQ10) deficiency due to loss‐of‐function mutations in COQ5 that encodes for an enzyme catalyzing the only C‐methylation in CoQ10 synthesis. Using whole genome sequencing, the authors have shown that a tandem duplication due to an unbalanced crossing‐over of AluY and AluYc led to the formation of a new isoform with an aberrant 3′UTR. Oral CoQ10 supplementation led to improvement of CoQ10 in the blood and subsequent clinical improvement. |
---|---|
Bibliography: | Funding information These authors contributed equally to the manuscript. Communicated by David S. Rosenblatt Contract Grant Sponsors: Intramural Research Program of the National Institutes of Health, and the Common Fund, Office of the Director; National Human Genome Research Institute; Common Fund, Office of the Director; National Institutes of Health (RO1‐N5021328‐030 and RO1OD010944‐05); U.S. Department of Defense (PR150585P1); Wellcome Centre for Mitochondrial Research (203105/Z/16/Z); Medical Research Council (MRC) Centre for Translational Research in Neuromuscular Disease, Mitochondrial Disease Patient Cohort (UK) (G0800674); Lily Foundation; UK NHS. These authors contributed to the manuscript and are senior authors. ObjectType-Case Study-2 SourceType-Scholarly Journals-1 ObjectType-Feature-4 content type line 23 ObjectType-Report-1 ObjectType-Article-3 These authors contributed to the manuscript and are senior authors These authors contributed equally to the manuscript |
ISSN: | 1059-7794 1098-1004 |
DOI: | 10.1002/humu.23345 |